Equities analysts expect Elanco Animal Health (NASDAQ:ELAN) to announce earnings of $0.23 per share for the current quarter, Zacks reports. Two analysts have provided estimates for Elanco Animal Health’s earnings. The highest EPS estimate is $0.24 and the lowest is $0.20. The business is scheduled to announce its next quarterly earnings report on Wednesday, May 1st.

On average, analysts expect that Elanco Animal Health will report full-year earnings of $1.09 per share for the current fiscal year, with EPS estimates ranging from $1.08 to $1.10. For the next fiscal year, analysts forecast that the business will report earnings of $1.29 per share, with EPS estimates ranging from $1.21 to $1.32. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Elanco Animal Health.

Elanco Animal Health (NASDAQ:ELAN) last released its quarterly earnings data on Wednesday, February 6th. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.03. The business had revenue of $799.30 million during the quarter, compared to the consensus estimate of $804.07 million. The firm’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the business posted $0.12 earnings per share.

Several research analysts recently commented on the stock. UBS Group initiated coverage on shares of Elanco Animal Health in a report on Wednesday, March 20th. They issued a “sell” rating and a $28.00 price objective for the company. Zacks Investment Research upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Tuesday. Credit Suisse Group reiterated a “hold” rating and issued a $33.00 target price on shares of Elanco Animal Health in a research note on Friday, January 4th. Morgan Stanley assumed coverage on shares of Elanco Animal Health in a research report on Wednesday, March 13th. They set an “equal weight” rating and a $34.00 price objective on the stock. Finally, Argus assumed coverage on shares of Elanco Animal Health in a research report on Tuesday, January 15th. They set a “buy” rating and a $37.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $33.22.

ELAN opened at $32.74 on Wednesday. Elanco Animal Health has a 12 month low of $28.00 and a 12 month high of $37.61.

In other Elanco Animal Health news, Director R David Hoover bought 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were bought at an average price of $31.43 per share, for a total transaction of $628,600.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

A number of institutional investors have recently made changes to their positions in ELAN. JPMorgan Chase & Co. bought a new stake in Elanco Animal Health in the 3rd quarter worth $38,358,000. Alliancebernstein L.P. bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $27,131,000. Janus Henderson Group PLC bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $68,975,000. CI Investments Inc. bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $6,106,000. Finally, BlackRock Inc. bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $32,247,000.

About Elanco Animal Health

There is no company description available for Elanco Animal Health Inc

Featured Story: Guidelines for Successful Channel Trading

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.